Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): Analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)

Anti-Cancer Drugs

Volumn 25, Issue 2, 2014, Pages 212-218

  Modest, Dominik P ^a   Schulz, Christoph ^a   Von Weikersthal, Ludwig F ^c   Quietzsch, Detlef ^d   Von Einem, Jobst C ^a   Schalhorn, Andreas ^a   Vehling Kaiser, Ursula ^e   Laubender, Rüdiger P ^b,f   Giessen, Clemens ^a   Stintzing, Sebastian ^e   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c KLINIKUM ST MARIEN   (Germany)

^d KLINIKUM CHEMNITZ   (Germany)

^e Onkologische Praxis   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

colorectal cancer; FuFIRI; hindgut; midgut; mIROX; outcome

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HINDGUT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDGUT; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; YOUNG ADULT;

EID: 84891890447     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000041     Document Type: Article

References (25)

1. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: Results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13:308-317
2. Giessen C, Stintzing S, Laubender RP, Ankerst DP, Schulz C, Moosmann N, et al. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10: 317-324
3. Oliner KS, Douillard JY, Siena S, Tabernero T, Burkes RL, Barugel ME, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC) [abstract]. J Clin Oncol 2013; 31 (Suppl):3511
4. Van Cutsem E, Köhne CH, Làng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011-2019
5. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104:856-862
6. Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, et al. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. Int J Cancer 2012; 131: 980-986
7. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatinbased first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377:2103-2114
8. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-671
9. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010; 28:4697-4705
10. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357:2040-2048
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-1765
12. Amado RG,Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634
13. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002; 101:403-408
14. Carethers JM. One colon lumen but two organs. Gastroenterology 2011; 141:411-412
15. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113: 779-788
16. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 2004; 88:261-266
17. Albuquerque C, Bakker ER, van Veelen W, Smits R. Colorectal cancers choosing sides. Biochim Biophys Acta 2011; 1816: 219-231
18. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: A tale of two sides or a continuum? Gut 2012; 61:794-797
19. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53:57-64
20. Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G, Smith MA. Mortality by stage for right- versus left-sided colon cancer: Analysis of surveillance, epidemiology, and end results - Medicare data. J Clin Oncol 2011; 29:4401-4409
21. Missiaglia E, Jacobs B, Di Narzo AF, Soneson C, Roth A, Bosman F, et al. Proximal and distal colon tumors as distinct biologic entities with different prognoses [abstract]. J Clin Oncol 2013; 31 (Suppl):3526
22. Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, et al. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17 [abstract]. J Clin Oncol 2013; 31 (Suppl):3528
23. Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47:206-214
24. Maus MKH, Hanna DL, Stephens C, Grimminger PP, Epstein M, Astrow SH, et al. Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum) [abstract]. J Clin Oncol 2013; 31 (Suppl):3527
25. Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61:847-854